Article info
Respiratory research
Original article
A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice
- Correspondence to Dr John D Campbell, Dynavax Technologies, 2929 7th St, Ste 100, Berkeley, CA 94710, USA; dcampbell{at}dynavax.com
Citation
A limited CpG-containing oligodeoxynucleotide therapy regimen induces sustained suppression of allergic airway inflammation in mice
Publication history
- Received October 3, 2013
- Revised December 24, 2013
- Accepted January 9, 2014
- First published January 24, 2014.
Online issue publication
May 14, 2014
Article Versions
- Previous version (24 January 2014).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Files in this Data Supplement:
- Data supplement 1 - Online supplement
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions